{"id":"NCT02432144","sponsor":"Ultragenyx Pharmaceutical Inc","briefTitle":"A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)","officialTitle":"A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-10","primaryCompletion":"2019-01-14","completion":"2019-01-14","firstPosted":"2015-05-01","resultsPosted":"2019-07-30","lastUpdate":"2020-07-30"},"enrollment":12,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Sly Syndrome","MPS VII","Mucopolysaccharidosis","Mucopolysaccharidosis VII"],"interventions":[{"type":"DRUG","name":"UX003","otherNames":["recombinant human beta-glucoronidase","rhGUS","Mepsevii â„¢","vestronidase alfa","vestronidase alfa-vjbk"]}],"arms":[{"label":"UX003","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the long-term safety of UX003 in subjects with MPS 7.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation","timeFrame":"From first dose of study drug until 30 days after the last dose of study drug. Mean duration of UX003 treatment was 100.5 weeks.","effectByArm":[{"arm":"UX003","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":7},"locations":{"siteCount":7,"countries":["United States","Brazil","Mexico","Portugal"]},"refs":{"pmids":["32063397","37415957","33874971"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":12},"commonTop":["Upper Respiratory Tract Infection","Infusion Site Extravasation","Vomiting","Cough","Urticaria"]}}